- 5 Health Care Leaders on U.S. Medicine's Trust DeficitIn a wide-ranging dinner conversation, health leaders from Toby Cosgrove to Arianna Huffington discussed why patients don't trust U.S. medicine and data use—and how to fix it.
- The Startup Bringing Video Counseling to Thailand to Combat Therapy StigmaLong wait times, limited availability in rural areas, and societal stigma around mental illness can contribute to a tricky environment for people struggling with their mental health.
- The Gene Therapy Spree Rolls on With $3 Billion Astellas DealJapan's Astellas is snatching up Audentes Therapeutics in a $3 billion gene therapy deal—part of a growing trend among pharma companies.
- Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on VapingDr. Stephen Hahn was approved by a Senate panel to lead the FDA on Tuesday. But he faced scrutiny on the future of vaping and e-cig regulation.
- Biogen Stock Tumbles on Brutal Takedown of Its Alzheimer's Drug BetBiogen revived an Alzheimer's drug that had been left for dead. But at least one analyst is pouring cold water on the aducanumab bet, and Biogen stock fell Monday.
- Dexcom Software Outage Draws Fury from Diabetes Patients' ParentsDexcom's popular glucose monitoring software alerts went dark over Thanksgiving weekend, enraging the parents of children with diabetes.
- Why the Results of DNA Tests in the U.S. and China Left One Reporter Worried"I was handing over my genetic code to a country where the government has been accused of using DNA testing to profile minority groups—a concern that hit home when the results showed I was a member of one," writes K. Oanh Ha.
Skip to Content